Vipadenant
Modify Date: 2024-01-10 15:36:59
Vipadenant structure
|
Common Name | Vipadenant | ||
|---|---|---|---|---|
| CAS Number | 442908-10-3 | Molecular Weight | 321.33700 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C16H15N7O | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of VipadenantVipadenant is an adenosine receptor antagonist, with Kis of 1.3 nM and 68 nM for A2A and A1, respectively. |
| Name | 3-[(4-amino-3-methylphenyl)methyl]-7-(furan-2-yl)triazolo[4,5-d]pyrimidin-5-amine |
|---|---|
| Synonym | More Synonyms |
| Description | Vipadenant is an adenosine receptor antagonist, with Kis of 1.3 nM and 68 nM for A2A and A1, respectively. |
|---|---|
| Related Catalog | |
| Target |
Ki: 1.3 nM (A2A), 68 nM (A1)[1], 1005 nM (A3)[2] |
| In Vivo | Vipadenant (0.3-30 mg/kg) produces a dose-dependent reduction in catalepsy. Vipadenant (10 mg/kg) does not produce any statistically significant dyskinetic episodes in 6-OHDA-lesioned rats during a 19-day dosing regimen[1]. In the mouse and rat haloperidol-induced hypolocomotion models, vipadenant has a minimum effective dose of 0.1 and 1 mg/kg, respectively. Vipadenant (3 and 10 mg/kg, p.o.) is able to increase contralateral rotations in 6-OHDA lesioned rats[2]. |
| References |
| Molecular Formula | C16H15N7O |
|---|---|
| Molecular Weight | 321.33700 |
| Exact Mass | 321.13400 |
| PSA | 122.40000 |
| LogP | 2.51370 |
| Storage condition | 2-8℃ |
|
~91%
Vipadenant CAS#:442908-10-3 |
| Literature: BIOGEN IDEC MA INC.; VERNALIS RESEARCH LIMITED Patent: WO2008/86201 A1, 2008 ; Location in patent: Page/Page column 21 ; WO 2008/086201 A1 |
|
~%
Vipadenant CAS#:442908-10-3 |
| Literature: Gillespie, Roger J.; Bamford, Samantha J.; Botting, Ruth; Comer, Mike; Denny, Sarah; Gaur, Suneel; Griffin, Michael; Jordan, Allan M.; Knight, Anthony R.; Lerpiniere, Joanne; Leonardi, Stefania; Lightowler, Sean; McAteer, Steven; Merrett, Angela; Misra, Anil; Padfield, Antony; Reece, Mark; Saadi, Mona; Selwood, Daniel L.; Stratton, Gemma C.; Surry, Dominic; Todd, Richard; Tong, Xin; Ruston, Vicki; Upton, Rebecca; Weiss, Scott M. Journal of Medicinal Chemistry, 2009 , vol. 52, # 1 p. 33 - 47 |
![7-(furan-2-yl)-3-(3-methyl-4-nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine structure](https://image.chemsrc.com/caspic/432/442908-07-8.png)
![7-(2-furyl)-1H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine structure](https://image.chemsrc.com/caspic/127/442906-78-7.png)
| Precursor 2 | |
|---|---|
| DownStream 0 | |
| VER-ADO-49 |
| VER-A00-11 |
| Vipadenant |
| V-2006 |
| CEB-4520 |
| UNII-LDR3USH1NJ |